🌐 EN ▾
  • EN - English
  • FR - French
  • DE - German
  • JP - Japanese
  • KR - Korean

Liposomal

NADH

Advanced Cellular Energy &
Cognitive Performance Support
Athlete

NADH - The Power Behind Cellular Energy

NADH (reduced nicotinamide adenine dinucleotide) is a critical coenzyme present in all living cells and plays a central role in mitochondrial ATP production by acting as an electron donor in the electron transport chain. It supports cellular metabolism, energy generation, and neurological function.

Barriers to Effective Bioavailability

Gastrointestinal and Systemic
Degradation

Restricted Cellular uptake and Mitochondrial Molecular Barriers

Sensitivity to Oxidation, Acid sensitivity and low Oral stability

The Liposomal NADH Advantage

Liposomal NADH formulated with DFS Technology™ (Dietary Fiber Stabilized) utilizes an advanced phospholipid delivery system to help protect NADH during digestion and enhances cellular uptake. This optimized delivery approach improves stability and bioavailability, supporting mitochondrial energy production, sustained vitality, cognitive performance, and overall cellular resilience.

Grade/Specification Available Form
Liposomal NADH – 50% Powder
Backed by Science, Proven in Research

Analytical Validation: TEM, zeta potential, and particle size measurements confirm uniform, stable liposomes for reliable quality and nutrient delivery.

Liposomal NADH Core Benefits

Enhances cognitive performance and mental clarity

Brain Icon

Supports mitochondrial energy production

Energy Icon

Why Liposomal NADH is Superior?

Feature
Liposomal NADH
Conventional NADH
Absorption Technology
DFS Technology™ – advanced liposomal delivery
Basic form – poor absorption
Stability & Efficacy
Protected from degradation, stable & potent
Unstable, gastrointestinal and systemic degradation
Analytical Validation
TEM, Zeta, PDI advanced validation
No advanced validation
Tolerance
Gentle and effective delivery
May require higher doses, limited efficacy

Backed by External Peer-Reviewed Research

Drugs Under Experimental and Clinical Research

STUDY YEAR | 2004 | Demarin V et al.

Treatment of Alzheimer's disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study ...

READ THE STUDY

ELSEVIER | Annals of Allergy, Asthma & Immunology

STUDY YEAR | 1999 | Forsyth LM et al.

Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. NADH ...

READ THE STUDY

ELSEVIER | Revista ClĂ­nica EspaĂąola

STUDY YEAR | 2010 | Alegre J et al.

Nicotinamide adenine dinucleotide (NADH) in patients with chronic fatigue syndrome. Oral NADH ...

READ THE STUDY

Puerto Rico Health Sciences Journal

STUDY YEAR | 2004 | Santaella ML et al.

Comparison of oral nicotinamide adenine dinucleotide (NADH) versus conventional therapy for chronic fatigue syndrome ...

READ THE STUDY

Š 2026 LipsoBioŽ All Rights Reserved.

Disclaimer -

Please note that this website and the information provided are not intended for end consumers of finished food, beverage, dietary supplement, or cosmetic products, as the content here does not pertain to consumer-ready finished products. The statements related to ingredients on the website has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. By continuing to browse, you acknowledge and accept the terms outlined above.

top